Skip to main content
Hanmi Pharm. Co., Ltd. logo

Hanmi Pharm. Co., Ltd. — Investor Relations & Filings

Ticker · 128940 ISIN · KR7128940004 LEI · 988400PP10VZVUOFE672 KO Manufacturing
Open in API
Filings indexed 514 across all filing types
Latest filing 2026-06-05 Major Shareholding Noti…
Country KR South Korea
Listing KO 128940

About Hanmi Pharm. Co., Ltd.

https://www.hanmipharm.com/

Hanmi Pharm. Co., Ltd. is a research-oriented biopharmaceutical company focused on the development, manufacturing, and commercialization of pharmaceutical products. Its portfolio includes prescription drugs, over-the-counter (OTC) medicines, and raw materials. The company dedicates a significant portion of its revenue to in-house research and development, creating a robust pipeline of innovative therapies. A key unique selling point is its proprietary LAPSCOVERY platform technology, which is used to develop long-acting biologics. Hanmi's R&D efforts are concentrated on key therapeutic areas, including metabolic diseases, oncology, and rare diseases. The company actively collaborates with global partners to advance its clinical programs and bring novel treatments to the market.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification Classification · 95% confidence The document is a Korean ‘임원ㆍ주요주주 특정증권등 소유상황보고서’ (Report on ownership status of certain securities by executives and major shareholders) filed with the Financial Services Commission and Korea Exchange. It details the National Pension Service’s shareholdings and changes in percentage (crossing the 10% threshold). This corresponds to a major shareholding notification (MRQ), as it reports threshold-crossing ownership changes by a significant shareholder.
2026-06-05 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification Classification · 90% confidence The document is a mandatory report filed with the Korean Financial Services Commission and Korea Exchange detailing the ownership of specific securities by an officer/major shareholder (the National Pension Service) in Hanmi Pharmaceutical as of May 29, 2026. It is a shareholding notification related to crossing/exceeding the 10% ownership threshold, clearly fitting the Major Shareholding Notification category.
2026-06-01 Korean
기업지배구조보고서공시
Governance Information Classification · 92% confidence The document is a detailed ‘기업지배구조보고서’ (Corporate Governance Report) covering governance policies, board structure, compliance with governance indicators, shareholder meeting procedures, etc. It is a substantive governance report rather than a mere announcement or a different filing. This aligns with the Governance Information (CGR) category.
2026-06-01 Korean
투자판단관련주요경영사항 (소네페글루타이드 (Sonefpeglutide; LAPS GLP2 agonist; HM15912) 기술이전 계약 체결)
Regulatory Filings Classification · 85% confidence The document is a standalone disclosure of a material technology transfer (license) contract (투자판단 관련 주요경영사항) with details of counterparty, terms, milestones, royalties and board resolution date. There are no financial statements, no management change, no share issue, no acquisition or dividend, and it simply announces a significant contract under regulatory requirements. It is not a full report (e.g., annual or interim), nor a proxy, nor an investor presentation. Therefore it falls into the fallback category of general regulatory filings.
2026-06-01 Korean
투자판단관련주요경영사항 (HCP18034 개발을 위한 식약처(MFDS) 제3상 임상시험 계획 승인)
Regulatory Filings Classification · 85% confidence The document is a Korean stock exchange regulatory disclosure titled “투자판단 관련 주요경영사항” announcing MFDS Phase 3 clinical trial approval for HCP1803-4. It is not a financial report, earnings release, management change, or capital action. It is a general regulatory announcement of a material business event and thus falls under the fallback category Regulatory Filings (RNS).
2026-05-29 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 90% confidence The document is a statutory Korean regulatory filing titled “Report on the Ownership of Certain Securities by Officers and Major Shareholders” submitted to the Financial Services Commission and Korea Exchange. It details insider shareholdings and the daily changes (acquisitions/disposals) by the National Pension Service (an institutional investor), including precise share counts, dates, and transaction types. This is a classic insider share transaction and holdings report (director’s dealing).
2026-05-22 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.